Section A: Overview

1. Purpose of the report

1.1 The report informs the Board of the Governance Committee’s recommendations for Board and committee membership.

2. Recommendations

2.1 At its meeting on 23 March 2011, the Governance Committee made the following recommendations to the Board for the appointment of:

   (a) Ronald Brus as Board Member representing the industrialised country vaccine industry in the seat currently occupied by Jean Stéphenne effective immediately and until 31 July 2014.

   (b) Olga Popova as Alternate Board Member representing the industrialised country vaccine industry in the seat currently occupied by Sian Clayden effective immediately and until 31 July 2014.

   (c) Mahima Datla as Board Member representing the developing country vaccine industry in the seat currently occupied by Suresh Jadhav effective immediately and until 31 July 2014.

2.2 Further, at its meeting on 23 March 2011, the Governance Committee made the following recommendations for the appointment to the committees of:

   (a) Suresh Jadhav as Committee Delegate of the developing country vaccine industry to the Programme and Policy Committee effective immediately and until the committees are refreshed for the 2012 year.
(b) **Klaus Stohr** as Committee Delegate of the industrialised country vaccine industry to the Programme and Policy Committee in the seat currently held by Olga Popova effective immediately and until the committees are refreshed for the 2012 year.

(c) **Rob Moodie** as an independent member of the Evaluation Advisory Committee effective immediately and until his successor is elected and qualified.

(d) **Mira Johri** as an independent member of the Evaluation Advisory Committee effective immediately and until her successor is elected and qualified.

(e) **Stanley Foster** to be reclassified as an independent member of the Evaluation Advisory Committee effective immediately and until his successor is elected and qualified.

2.3 The Governance Committee will be considering the following candidates at its 6 July 2011 meeting for recommendation to the Board for the appointment of:

(a) **Geeta Rao Gupta** as Board Member representing UNICEF in the seat currently occupied by Saad Houry effective immediately and until her successor is appointed and qualified.

(b) **José Luis Solano** as Board Member representing donor governments Spain and Italy effective immediately and until 31 December 2011.

(c) **Amie Batson** as Board Member representing donor governments USA, Canada, Australia, Japan, and Korea reappointed until 31 December 2013.

(d) **Jenny Da Rin** as Alternate Board Member to Amie Batson representing donor governments USA, Canada, Australia, Japan, and Korea in the seat currently occupied by Murray Proctor effective immediately and until 31 December 2013.

(e) **Fatchou Gakaitangou** as Alternate Board Member to Toupta Boguena representing developing country governments effective immediately and until 31 July 2012.

(f) **Suresh Jadhav** as Alternate Board Member to Mahima Datla representing the developing country vaccine industry effective immediately and until 31 July 2012.

2.4 The Governance Committee will be considering the following candidates at its 6 July 2011 meeting for the appointment to the committees of:
(a) **Ronald Brus** as a member of the Executive Committee in the seat currently occupied by Suresh Jadhav effective immediately and until 31 December 2012.

(b) **Cristian Baeza** as a member of the Executive Committee in the seat currently occupied by Armin Fidler effective immediately and until 31 July 2014.

(c) **Geeta Rao Gupta** as a member of the Executive Committee in the seat currently occupied by Saad Houry effective immediately and until 31 July 2014.

(d) **Derek Strocher** in place of Natalia Antsilevich as Committee Delegate of the World Bank to the Audit and Finance Committee effective immediately and until the committees are refreshed for the 2012 year.

(e) **Micheline Gilbert** as Committee Delegate of donor governments USA, Canada, Australia, Japan, Korea to the Audit and Finance Committee effective immediately and until the committees are refreshed for the 2012 year.

(f) **José Luis Solano** as a member of the Governance Committee effective immediately and until the committees are refreshed for the 2012 year.

(g) **Olga Popova** as a member of the Governance Committee in the seat currently occupied by Sian Clayden effective immediately and until the committees are refreshed for the 2012 year.

(h) **Sania Nishtar** as Chair of the Evaluation Advisory Committee in place of Bernhard Schwartlander effective 23 September 2011 and until the committees are refreshed for the 2012 year.

2.5 The Governance Committee will also be asked to recommend the following adjustments:

(a) The terms of all members of the Evaluation Advisory Committee appointed for the first time at the Board meeting on 7-8 July 2011 would commence effective immediately and last until 31 July 2014. The terms of all existing members of the Evaluation Advisory Committee will expire three years after the date of original appointment.

(b) Suresh Jadhav’s appointment to the PPC will be as a member, rather than as a Committee Delegate since he is standing for appointment as an Alternate Board Member.
2.6 The Board is requested to consider and, if thought fit, appoint the candidates the Governance Committee recommends, and adjust the terms of Evaluation Advisory Committee members.

2.7 In practical terms, the terms of all candidates will commence on 9 July 2011. Those new candidates who will be representing their constituency at the 7-8 July 2011 Board meeting will be listed as Governance Committee recommendations in the list of attendees and not counted toward quorum (unless specifically appointed at the beginning of the meeting).

2.8 The Governance Committee Chair will report the outcome of the Committee’s considerations during his oral report to the Board on 8 July 2011.

3. Executive summary

3.1 The Governance Committee received biographies of the listed candidates. Those biographies are listed in section C of this report.

3.2 The Board is asked to note that the appointment of Micheline Gilbert to the Audit and Finance Committee would be the fourth committee appointment for the USA/Canada/Australia/Japan/Korea donor seat. The constituency is seeking an exception to the By-Law provision that states “[e]ach Board Member (taken together with his or her Alternate or any Committee Delegate…) shall normally be a member of at least one but no more than three Board Committees (including the Executive Committee).” (Article 4.2). This nomination is being made on the basis that Micheline Gilbert is representing the interests of the entire donor constituency and has received support from the donor constituencies.

3.3 The Evaluation Advisory Committee members do not have defined terms. It is thought a better practice that terms for this Committee be set at three years.

3.4 The Board is asked to note that the Governance Committee has restarted the recruitment process with its current recruitment consultant (EZI) to fill two of the vacancies for Unaffiliated Board Members. The remaining two vacancies are anticipated to be filled through direct approaches to identified candidates. This subcommittee is now comprised of George W Wellde, Jr (Chair), Dagfinn Høybråten, Anne Schuchat, Wayne Berson, and Helen Evans (non-voting).
4. Next steps

4.1 No further steps are required.

5. Conclusions

5.1 The Board is asked to consider these recommendations.

Section B: Implications

6. Impact on countries

6.1 There is no direct impact.

7. Impact on the Business Plan / Budget / Programme Financing

7.1 There is no direct impact.

8. Risk implications and mitigations

8.1 There is capacity risk for the Board if recommended candidates are not appointed and empty seats are not quickly filled after terms expire.

9. Legal and governance implications

9.1 There are no legal or governance implications other than those already highlighted in section 3 of this paper.

10. Consultation

10.1 UNICEF and World Bank senior management nominate candidates for their Board and committee seats.

10.2 Donor governments are responsible for nominating candidates for their seats in accordance with their constituency processes.

10.3 A Developing Country Government Board Member nominates a candidate for his/her alternate in accordance with his/her constituency process.
10.4 The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) nominates candidates for the industrialised country vaccine industry seat in accordance with its constituency process.

10.5 The Developing Countries Vaccine Manufacturers Network (DCVMN) nominates candidates for the developing country vaccine industry seat in accordance with its constituency process.

10.6 Independent members of the Evaluation Advisory Committee are identified through canvassing of current members of the Committee and other experts in the monitoring and evaluation community.

10.7 The Governance Committee made recommendations at its 23 March 2011 meeting and will make further recommendations at its 6 July 2011 meeting to the Board at this meeting.

11. Gender equality implications

11.1 The Board currently has 23 members (including the non-voting interim CEO):

(a) 18 members are men (78%), 5 are women (22%).

(b) Should all new primary Board Members listed in this document be appointed, the Board would have 24 members and the new composition would be 17 men (71%), 7 women (29%).

11.2 The Board currently has 16 Alternate Board Members:

(a) 11 alternates are men (69%), 5 are women (31%)

(b) Should all new alternate members listed in this document be appointed, there would be 17 total alternate members, and the new composition would be 12 men (71%), 5 women (29%).

12. Implications for the Secretariat

12.1 There are no implications on the Secretariat.
Section C: Profiles (listed by constituency)

13. World Bank

13.1 Cristian Baeza is the Board member representing the World Bank. Currently, he is the Director for Health, Nutrition and Population at the World Bank. Previous to rejoining the Bank, Dr. Baeza was a Partner in McKinsey and Company leading the Global Health Systems Financing group (Health Systems Policy, Financing, and Health Insurance). Cristian is a Medical Doctor from the University of Chile and holds a Master of Health Policy and Financing from Johns Hopkins University, and completed a Master in Neurosciences Program from the University of Chile, and a Master level program in Development and Social Policy from ILADES.

13.2 Derek Strocher is Senior Financial Officer with the World Bank’s Multilateral Trusteeship and Innovative Financing group. Derek leads the Bank’s efforts with respect to several funds, and plays an important role in the creation and design of future funds to achieve the Bank’s overall goals. Previously, Derek was Senior Director and Head of the Corporate Finance Initiatives team at Royal Bank of Scotland where he was a key player building RBS’s Strategic Finance franchise and twice received the UK CEO Outstanding Achiever Award. He has also held positions at Brake Brothers and Nexen in accounting, treasury, corporate finance, restructuring, investor relations, and acquisition roles. Derek completed a Masters degree from London Business School.

14. UNICEF

14.1 Geeta Rao Gupta is UNICEF’s Deputy Executive Director. Previously, she was a Senior Fellow at the Bill & Melinda Gates Foundation where she advised the president and leadership of the Global Development Program on their strategies and offered insight on managing projects to achieve the greatest impact. Prior to joining the foundation, Dr. Rao Gupta was president of the International Center for Research on Women (ICRW), a position she assumed in 1997 after serving in a variety of roles including consultant, researcher and officer. She is the recipient of numerous awards, including Harvard University’s 2006 Anne Roe Award and the 2007 Washington Business Journal’s “Women Who Mean Business” Award. Dr. Rao Gupta has her bachelor’s, master’s, and master of philosophy degrees in psychology from the University of Delhi, and a doctorate in philosophy from Bangalore University in India.
15. Donor governments

15.1 Ambassador José Luis Solano is a senior diplomat with 32 years of extensive experience in the diplomatic field, including monitoring Spanish cooperation projects. From August 2006, he was Deputy Director General in the Foreign Affairs Office for Asia and the Pacific. He was also Ambassador on Special Mission of Political Reconstruction and Stabilisation in Afghanistan. He has also served as Spain’s ambassador to Cameroon, the Central African Republic, and Chad. He holds both a law degree and a diploma of international studies.

15.2 Amie Batson is the current board member representing donor country governments USA/Canada/Australia/Japan/Korea. She joined USAID as Deputy Assistant Administrator for Global Health and USAID Deputy of the Global Health Initiative (GHI) following a 20-year career in global health that included positions in the WHO, UNICEF, and most recently, the World Bank. As one of the original members of the GAVI Alliance, she led the World Bank’s efforts in vaccine financing, including the establishment of new financing mechanisms like the Advance Market Commitment and the use of donor financing to “buy-down” loans from the International Development Assistance program. These efforts provided billions of dollars for global health and helped to vaccinate millions of children against polio, pneumonia, diarrhea, and other vaccine preventable causes of death.

15.3 Jenny Da Rin is Assistant Director General, Health Education and Scholarships Branch, for AusAID. Prior to this she was Adviser to the Minister for Foreign Affairs and Senior Adviser to the Minister for Defence. She is a Fellow of the Australian Institute of Company Directors and of the Australian Rural Leadership Foundation. She earned her Master of Government and Commercial Law (with merit) from the Australian National University, a Graduate Diploma from Charles Sturt University, and BA from the University of Canberra.

15.4 Micheline Gilbert is Senior Analyst, Global Initiatives - Health, Multilateral for the Canadian International Development Agency. Prior to this she was Analyst for CIDA’s Mali Programme, and First Secretary for the High Commission of Canada in Mozambique. She has 19 years of experience in international development including analysis, design, implementation, monitoring, evaluation of large-scale projects and programmes, including budget support. She has a MA from the University of Sherbrooke, a graduate degree in international development from the Institute for International Cooperation and Development, and a BSc in economics from l’Université de Trois-Rivières.
16. Developing country governments

16.1 **Fatchou Gakaitangou** is Head of Integrated Management of Childhood Illness at the Ministry of Health of Chad. In the past he was Public Health Officer for the Health Sector Support Project funded by the World Bank and was National Leprosy Elimination Program manager. He has received two national awards for contribution to Cholera Epidemic Control and Leprosy Elimination in Chad. He earned his MD at Minsk in the former Soviet Union and his MPH from Tulane in the United States.

17. Developing country vaccine industry

17.1 **Mahima Datla** serves as the Senior Vice President for the Bio-Technology and Projects Division in Biological E. Ltd. She has been in charge of coordination for the development of cell culture based inactivated Japanese encephalitis vaccines in India in partnership with Intercell of Austria. During her time at BE, she has been involved in strategy and business development functions.

17.2 **Suresh Jadhav** is stepping down from the primary Board seat but has been recommended by DCMVN to remain on the Board as its Alternate Board Member for one year. Dr Jadhav serves as the Executive Director of Serum Institute of India Ltd. Prior to his current position, Dr Jadhav served on the WHO Strategic Advisory Group of Experts (SAGE) and was President of the Steering Committee of DCMVN. Dr Jadhav holds a masters degree in pharmacy from Nagpur University and his PhD from Haffkine Institute.

18. Industrialised country vaccine industry

18.1 **Ronald Brus** is Crucell’s President and Chief Executive Officer. He has been a member of Crucell’s Management Committee since the Company’s incorporation and was formerly Chief Operating Officer (March 2003 to January 2004) and Chief Business Officer (October 2000 to February 2003). Prior to that, he was Executive Vice President Business Development after joining the Company in 1997. From 1994 to 1996 he was product planning physician at Forest Laboratories in New York and from 1990 to 1994 he was Medical Director for Zambon B.V. He holds a medical degree from the University of Groningen, the Netherlands.

18.2 **Olga Popova** is currently the Head of Government Affairs & Public Health in Crucell, based in Switzerland, leading the policy development on International and European levels. She joined Crucell in 2007. Prior to that, Dr Popova gained her vaccinology experience at Novartis Vaccines, starting in 2001 as an Associate Director of Medical Affairs, where she
took care of numerous worldwide vaccines projects, covering the fields of influenza, meningitis and rabies. She also headed the Medical Support team, responsible for providing scientific and medical information services for infectious diseases and vaccines. Dr Popova worked for 10 years in the pharmaceutical sector, in a number of clinical development and medical affairs positions based in Europe. Dr Popova holds a dual Russian / Italian citizenship and obtained her medical degree from the University of Moscow in 1992. She is fluent in five languages.

18.3 **Klaus Stohr** is Global Director Influenza Franchises for Novartis Vaccines and Diagnostics. Prior to this he was Special Advisor on Influenza Pandemic Vaccine Development for the WHO Initiative for Vaccine Research. Dr Stohr has published more than 55 pieces. He received his PhD from the University of Leipzig, having written his dissertation on epidemiology and infectious disease control. He is a board member of the International Society for Influenza and Other Respiratory Virus Diseases.

19. **Evaluation Advisory Committee Chair and members**

19.1 **Sania Nishtar** is the founder and president of the NGO think tank, Heartfile, which today is the most powerful health policy voice in Pakistan and is recognized as a model for replication in other developing countries. Her areas of interests are health systems, global health, broader issues of governance and public-private relationships. She is the founder of Pakistan's Health Policy Forum and provides support to many agencies in an advisory role. She is a member of the board of the International Union for Health Promotion and the Alliance for Health Policy and Systems Research. She is also a member of the World Economic Forum's Global Agenda Council, the Clinton Global Initiative, the Ministerial Leadership Initiative for Global Health and many other international initiatives.

19.2 **Rob Moodie** is the inaugural Chair of Global Health at the Nossal Institute for Global Health, University of Melbourne. He has 30 years experience in planning and evaluating health programs in Australia, Africa, Asia and the Pacific. He was the inaugural Director of Country Support for UNAIDS in Geneva from 1995-98, and the CEO of VicHealth from 1998-2007. He is Chair of the National Preventative Health Taskforce and was a member of the Commission on AIDS in the Pacific. He chaired the technical advisory panel of Avahan, the Gates Foundation's HIV prevention program in India, from 2004-2009. He has particular interests in non–communicable diseases, HIV/AIDS and teaches a number of courses here and in Mozambique on public health leadership and health promotion. He has co-edited and co-authored four books including Promoting Mental Health, Hands on Health Promotion and his latest, Recipes for a Great Life written with Gabriel Gate.
19.3 **Mira Johri** is an Associate Professor and Researcher at the University of Montréal. Her research aims to contribute to global health by strengthening the capacity to evaluate, prioritise and improve the efficiency of health-related strategies and interventions. It makes use of quantitative economic evaluation methods and aims to better integrate concerns for equity and fairness—in addition to more commonly studied criteria such as those related to efficiency—into the formation of health policies. She received her PhD at McGill University and her MPH at Yale University.

19.4 **Stanley Foster** is Professor, Hubert Department of Global Health, Rollins School of Public Health at Emory University, where he has been since 1994. From 1980 to 1994, Professor Foster worked with the International Health Programme Office at the CDC in its Combating Childhood Communicable Disease Project. He graduated from Williams College in 1955 and the University of Rochester School of Medicine in 1960.